The observed cytotoxic effect of DMF was significantly higher after 72 h of treatment in tumor samples with a KRAS mutation (mean cell survival: 48.3% and 81.3% in tumours with and without KRAS mutation, respectively; p < 0.01) after DMF treatment (Figure 1D). The gene discussed is KRAS; the disease is neoplasm.